[{"Assets_0_Q2_USD":516532000.0,"CommonStockSharesOutstanding_0_Q2_shares":293727630.0,"EarningsPerShareBasic_1_Q2_USD":0.06,"EarningsPerShareBasic_2_Q2_USD":0.12,"EarningsPerShareDiluted_1_Q2_USD":0.06,"EarningsPerShareDiluted_2_Q2_USD":0.11,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":74393000.0,"NetIncomeLoss_1_Q2_USD":17656000.0,"NetIncomeLoss_2_Q2_USD":34356000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":311219000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":310759000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":293188000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":292029000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20170802"}]